Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies Detected 1 Year After BNT162b2 Vaccination in Children.


Journal

The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858

Informations de publication

Date de publication:
30 Jul 2024
Historique:
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

Humoral immune responses after BNT162b2 vaccination are predominantly composed of immunoglobulin (Ig) G1 and IgG3 subclass antibodies. As previously described in adults, S1-specific and receptor-binding domain-specific IgG4 levels increase significantly 1 year after the second BNT162b2 vaccination in children 5-11 years of age. Understanding mRNA vaccine-specific IgG4 responses in all age groups is crucial as more mRNA vaccines will reach licensure in the coming years.

Identifiants

pubmed: 39078156
doi: 10.1097/INF.0000000000004488
pii: 00006454-990000000-00959
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaftn
ID : KFO296

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Références

Brown BD, Fauci AS, Belkaid Y, et al. RNA vaccines: a transformational advance. Immunity. 2023;56:2665–2669.
Lapuente D, Winkler TH, Tenbusch M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol. 2024;21:144–158.
Kaplonek P, Cizmeci D, Fischinger S, et al. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci Transl Med. 2022;14:eabm2311.
Mackin SR, Desai P, Whitener BM, et al. Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. Nat Microbiol. 2023;8:569–580.
Bartsch YC, Chen JW, Kang J, et al. BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children. npj Vaccines. 2022;7:158.
Irrgang P, Gerling J, Kocher K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. 2023;8:eade2798.
Kiszel P, Sík P, Miklós J, et al. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history. Sci Rep. 2023;13:13166.
Buhre JS, Pongracz T, Künsting I, et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front Immunol. 2023;13:1020844.
de Jong BG, IJspeert H, Marques L, et al. Human IgG2- and IgG4-expressing memory B cells display enhanced molecular and phenotypic signs of maturity and accumulate with age. Immunol Cell Biol. 2017;95:744–752.
Mayer L, Weskamm LM, Fathi A, et al. MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans. npj Vaccines. 2024;9:20.
Bremer L, Goletzke J, Wiessner C, et al. Paracetamol medication during pregnancy: insights on intake frequencies, dosages and effects on hematopoietic stem cell populations in cord blood from a longitudinal prospective pregnancy cohort. EBioMedicine. 2017;26:146–151.
Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Rev Immunol. 2023;23:763–778.
Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109–113.
Mudd PA, Minervina AA, Pogorelyy MV, et al.; SJTRC Study Team. (SJTRC Study Team) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell. 2022;185:603–613.e15.
Akiyama M, Suzuki K, Yasuoka H, et al. Follicular helper T cells in the pathogenesis of IgG4-related disease. Rheumatology (Oxford). 2018;57:236–245.
Thomas AL, Godarova A, Wayman JA, et al. Accumulation of immune-suppressive CD4 + T cells in aging - tempering inflammaging at the expense of immunity. Semin Immunol. 2023;70:101836.

Auteurs

Robin Kobbe (R)

From the Institute for Infection Research and Vaccine Development.
Department of Infectious Disease Epidemiology.
German Centre for Infection Research, Hamburg, Germany.

Cornelius Rau (C)

From the Institute for Infection Research and Vaccine Development.
Department of Infectious Disease Epidemiology.

Ulf Schulze-Sturm (U)

Department of Pediatrics-Kinder-UKE.

Felix Stahl (F)

Division of Experimental Feto-Maternal Medicine, Department of Obstetrics and Fetal Medicine.

Luis Fonseca-Brito (L)

Division of Experimental Feto-Maternal Medicine, Department of Obstetrics and Fetal Medicine.

Anke Diemert (A)

Institute of Immunology.
Hamburg Center for Translational Immunology.

Marc Lütgehetmann (M)

Hamburg Center for Translational Immunology.

Marylyn M Addo (MM)

From the Institute for Infection Research and Vaccine Development.
Department for Clinical Immunology of Infectious Diseases, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.
German Centre for Infection Research, Hamburg, Germany.

Petra Arck (P)

Institute of Immunology.
Hamburg Center for Translational Immunology.

Leonie M Weskamm (LM)

From the Institute for Infection Research and Vaccine Development.
Department for Clinical Immunology of Infectious Diseases, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.
German Centre for Infection Research, Hamburg, Germany.

Classifications MeSH